Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients.
Cortiula F, Pasello G, Follador A, Nardo G, Polo V, Scquizzato E, Del Conte A, Miorin M, Giovanis P, D'Urso A, Girlando S, Settanni G, Picece V, Veccia A, Corvaja C, Indraccolo S, De Maglio G. Cortiula F, et al. Among authors: picece v. Diagnostics (Basel). 2020 Sep 28;10(10):765. doi: 10.3390/diagnostics10100765. Diagnostics (Basel). 2020. PMID: 32998450 Free PMC article.
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G. Munari E, et al. Among authors: picece v. Oncotarget. 2017 Oct 4;8(52):90123-90131. doi: 10.18632/oncotarget.21485. eCollection 2017 Oct 27. Oncotarget. 2017. PMID: 29163815 Free PMC article.
Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G. Munari E, et al. Among authors: picece v. Oncotarget. 2018 Dec 11;9(97):37077. doi: 10.18632/oncotarget.26475. eCollection 2018 Dec 11. Oncotarget. 2018. PMID: 30651938 Free PMC article.
Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer.
Martoni A, Guaraldi M, Piana E, Strocchi E, Petralia A, Busutti L, Preti P, Robustelli G, Raimondi M, Ferrara G, Palomba G, Lelli G, Picece V, Recaldin E, Caffo O, Ambrosini G, Sarobba G, Farris A, Pannuti F. Martoni A, et al. Among authors: picece v. Lung Cancer. 1998 Oct;22(1):31-8. doi: 10.1016/s0169-5002(98)00065-8. Lung Cancer. 1998. PMID: 9869105 Clinical Trial.
Sunitinib therapy in metastatic papillary thyroid cancer.
Gori S, Foglietta J, Rossi M, Hamzaj A, Stocchi L, Galuppo C, Picece V, Puxeddu E, Furlani L. Gori S, et al. Among authors: picece v. Tumori. 2013 Nov-Dec;99(6):285e-7e. doi: 10.1700/1390.15470. Tumori. 2013. PMID: 24503805
Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, Guaraldi M, Palomba G, Preti P, Petralia A, Artioli F, Picece V, Farris A, Mantovani L. Martoni A, et al. Among authors: picece v. Eur J Cancer. 2005 Jan;41(1):81-92. doi: 10.1016/j.ejca.2004.08.029. Eur J Cancer. 2005. PMID: 15617993 Clinical Trial.
17 results